Literature DB >> 11192322

Administering granulocyte colony-stimulating factor to acute liver failure patients corrects neutrophil defects.

N Rolando1, M Clapperton, J Wade, J Wendon.   

Abstract

OBJECTIVES: Neutrophil function is defective in acute liver failure (ALF) and the in vitro ability of granulocyte colony-stimulating factor (G-CSF) to reverse these defects has been reported. The effects of administering G-CSF to ALF patients are presented in this study.
DESIGN: This was a prospective, phase I/II, open label, study.
SETTING: The liver intensive therapy unit at King's College Hospital, London. PARTICIPANTS: Sequential patients admitted with acute liver failure due to acetaminophen overdose.
INTERVENTIONS: G-CSF was given to four groups (each n = 6) of ALF patients as a daily infusion at 25, 50, 100 or 150 microg/m2. A control group of eight patients did not receive G-CSF. MAIN OUTCOME MEASURES: Neutrophil phagocytosis and killing of Staphylococcus aureus and superoxide release before G-CSF administration and at 24 and 96 h thereafter.
RESULTS: Neutrophils from patients receiving 50, 100 or 150 microg/m2 G-CSF, but not from control patients or those receiving 25 microg/m2, showed significantly increased phagocytosis and killing at 96 h. Doses of 50 or 150 microg/m2 G-CSF resulted in increased superoxide production at 96 h. No patients discontinued treatment as a consequence of side effects related to G-CSF administration.
CONCLUSIONS: G-CSF administration is a safe and effective means of reversing the neutrophil defects of ALF, and may have a role in the prevention and treatment of infection in these patients. A dose of 50 microg/m2/day is as effective as higher doses and was associated with fewer side effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11192322     DOI: 10.1097/00042737-200012120-00010

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  11 in total

Review 1.  Treatment of breast cancer with chemotherapy in combination with filgrastim: approaches to improving therapeutic outcome.

Authors:  Giuseppe Frasci
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Stem cell-based therapies for liver diseases: state of the art and new perspectives.

Authors:  Anna Chiara Piscaglia; Mariachiara Campanale; Antonio Gasbarrini; Giovanni Gasbarrini
Journal:  Stem Cells Int       Date:  2010-09-01       Impact factor: 5.443

Review 3.  Overview on acute-on-chronic liver failure.

Authors:  Jing Zhang; Shan Gao; Zhongping Duan; Ke-Qin Hu
Journal:  Front Med       Date:  2016-03-14       Impact factor: 4.592

4.  Fulminant hepatic failure.

Authors:  Jelica Kurtovic; Stephen M Riordan; Roger Williams
Journal:  Curr Treat Options Gastroenterol       Date:  2005-12

5.  Effects of Granulocyte Colony-Stimulating Factor on Patients with Liver Failure: a Meta-Analysis.

Authors:  Qiao Yang; Ying Yang; Yu Shi; Fangfang Lv; Jiliang He; Zhi Chen
Journal:  J Clin Transl Hepatol       Date:  2016-06-15

6.  Altered PGE2-EP2 is associated with an excessive immune response in HBV-related acute-on-chronic liver failure.

Authors:  Yunyun Wang; Chao Chen; Jinjin Qi; Fengtian Wu; Jun Guan; Zhi Chen; Haihong Zhu
Journal:  J Transl Med       Date:  2019-03-19       Impact factor: 5.531

Review 7.  The Role of Monocytes and Macrophages in Acute and Acute-on-Chronic Liver Failure.

Authors:  Evangelos Triantafyllou; Kevin J Woollard; Mark J W McPhail; Charalambos G Antoniades; Lucia A Possamai
Journal:  Front Immunol       Date:  2018-12-14       Impact factor: 7.561

Review 8.  Acute kidney injury spectrum in patients with chronic liver disease: Where do we stand?

Authors:  Wiwat Chancharoenthana; Asada Leelahavanichkul
Journal:  World J Gastroenterol       Date:  2019-07-28       Impact factor: 5.742

Review 9.  Pathophysiology of cerebral oedema in acute liver failure.

Authors:  Teresa R Scott; Victoria T Kronsten; Robin D Hughes; Debbie L Shawcross
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 10.  Is there a place for granulocyte colony-stimulating factor in non-neutropenic critically ill patients?

Authors:  Elie Azoulay; Christophe Delclaux
Journal:  Intensive Care Med       Date:  2003-10-31       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.